TauRx Pharmaceuticals Ltd: LUCIDITY phase 3 topline data pre

- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY

Related Keywords

China , Canada , United Kingdom , Singapore , San Francisco , California , United States , Scotland , Kostenloser Wertpapierhandel , George Grossberg , Prnewswire Taurx Pharmaceuticals Ltd , St Louis University School Of Medicine , University Of Aberdeen , Clinical Trials , Director Division , Geriatric Psychiatry Department , Behavioural Neuroscience , Taurx , Pharmaceuticals , Lucidity , Hase , Topline , Data , Resented , Tad , Imtm , Only , Mural , Anti , Therapy , Gate , Stage , Development ,